Explore all of our publications and interviews in academic journals and mainstream media using the filter and search functions.
What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
CMS's Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs
The administration has proposed a loophole in the Medicaid Best Price rules that would dismiss linking the drug's effectiveness to its price.
HA Blog 07/06/2020
Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students
Medical students' education covers topics spanning health, disease, and treatment, but what about drug pricing and their role as prescribers?
Medical Science Educator 01/13/2021
Who Is Sowing Seeds of Confusion About The QALY?
Industry sponsorship of patient advocacy groups opposing the QALY threatens to undermine not just the QALY but also an objective analysis of policy decisions.
Health Affairs 07/24/2020
Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead
Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?
Value in Health 03/29/2021
US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Understanding the Rewards of Successful Drug Development: Thinking Inside the Box
The ability to charge high prices is only one component of a complex system of risks and rewards that underlies pharmaceutical innovation.
Medicare Negotiation: A "Too Little" or "Too Late" Framework for Drug Selection
Recent draft pieces of legislation and regulation take aim at the rising cost of drugs, targeting drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars.
Abandon Biosimilars as Biologics are Natural Monopolies
Biosimilars will not effectively lower the price of biologic drugs after the period of market exclusivity.
HA Blog 04/15/2019
List Price, Net Price, and the Rebate Caught in the Middle
Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.
JAMA Viewpoint 03/06/2019
Expansion of the Medicare 340B Payment Program
As the 340B program expands, it continues to draw national attention.
JAMA Viewpoint 12/11/2018
The "Netflix Model" of Financing Hepatitis C Treatment
An alternative payment model is proposed to support a population-level payment paradigm.
JAMA Viewpoint 11/20/2018
Cardiovascular Drugs Not Price Aligned with Value in US
U.S. prices of common cardiovascular drugs are not consistent with the cost-effectiveness evidence.
Health Affairs 08/01/2018
Perspective on National Coverage Analysis of CAR-T Therapies
Potential strategies for CMS's evaluation of coverage and payment for the various CAR-T therapies are laid out.
Spending On Prescription Drugs In The US: Where Does All The Money Go?
Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.
HA Blog 07/31/2018
Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath
Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price, but such contracts are ill-suited to do so.
Annals of Internal Medicine 06/19/2018
Association of Rebates in Part D with Patient OOP and Federal Spending
The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.
JAMA Internal Medicine 05/30/2017
No Results Found